FOXO Technologies Inc.™ (NYSEAM: FOXO), a leader in the field of
commercializing epigenetic biomarker technology, today announced
the launch of its cutting-edge Bioinformatics Services to
accelerate breakthroughs in biology, biotechnology, and healthcare,
and redefine the growing field of epigenetic research.
FOXO’s Bioinformatics Services offers a comprehensive platform
of advanced data solutions tailored to meet the specific needs of
clients in academia, healthcare, and pharmaceutical research.
Through its innovative suite of bioinformatic tools, FOXO will
enable its clients to increase the speed and accuracy with which
they process, analyze, and interpret data sets, accelerate
discoveries, and advance their understanding of complex
diseases.
“The launch of FOXO’s Bioinformatics Services marks a
significant milestone for FOXO Technologies and the field of
epigenetic research,” said Tyler Danielson, interim CEO and Chief
Technology Officer of FOXO. “Epigenetics plays a key role in gene
regulation and the interplay between lifestyle and environmental
factors on biological systems. However, harnessing the full
potential of epigenetic data has long been hindered by the
challenges of data processing, analysis, and interpretation. With
the introduction of our Bioinformatics Services, we aim to
eliminate these barriers and empower researchers, clinicians, and
other organizations to accelerate their research.”
Any researcher or research group that seeks to leverage DNA
methylation microarrays can benefit from FOXO’s Bioinformatics
Services. These services include ingesting and processing raw DNA
methylation microarray data, performing sample- and probe-level
quality control, and securely delivering publication-ready figures
and results. FOXO’s expert team also offers the addition of
advanced bioinformatic analyses including epigenome wide
association studies (EWAS), and even AI-driven epigenetic biomarker
development. These services can be applied to Illumina’s existing
human and mouse DNA Methylation arrays, which cover over 935,000
and 285,000 CpG sites respectively. By leveraging state-of-the-art
algorithms and world-class experts, the company’s bioinformatics
platform can rapidly deliver accurate and high-quality data
tailored to the needs of each client.
“Epigenetics is a nuanced science. Through years of experience,
our team has developed niche expertise in bioinformatics with
respect to epigenetics, specifically. Researchers who wish to
incorporate epigenetic data into their studies can save valuable
time and effort through our services offering,” says Brian Chen,
Chief Science Officer.
As a leader in the field, FOXO remains committed to advancing
epigenetic research and catalyzing breakthroughs in health and
longevity. With Bioinformatic Services, FOXO is also opening the
door to new research collaborations with industry and academic
leaders.
For more information about FOXO and their bioinformatic
services, please visit www.foxotechnologies.com.
About FOXO Technologies Inc. (“FOXO”):
FOXO is at the forefront of commercializing epigenetic biomarker
technology. Their mission is to utilize the power of epigenetics
and artificial intelligence to generate data-driven insights that
promote optimal health and longevity outcomes for individuals and
organizations alike.
Forward-Looking Statements
This press release contains certain forward-looking statements
for purposes of the “safe harbor” provisions under the United
States Private Securities Litigation Reform Act of 1995. Any
statements other than statements of historical fact contained
herein, including statements as to future results of operations and
financial position, planned products and services, business
strategy and plans, objectives of management for future operations
of FOXO, market size and growth opportunities, competitive position
and technological and market trends, are forward-looking
statements. Such forward-looking statements include, but are not
limited to, expectations, hopes, beliefs, intentions, plans,
prospects, financial results or strategies regarding FOXO and the
future held by the management team of FOXO, the future financial
condition and performance of FOXO and the products and markets and
expected future performance and market opportunities of FOXO. These
forward-looking statements generally are identified by the words
“anticipate,” “believe,” “could,” “expect,” “estimate,” “future,”
“intend,” “strategy,” “may,” “might,” “strategy,” “opportunity,”
“plan,” “project,” “possible,” “potential,” “predict,” “scales,”
“representative of,” “valuation,” “should,” “will,” “would,” “will
be,” “will continue,” “will likely result,” and similar
expressions, but the absence of these words does not mean that a
statement is not forward-looking. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the risk of changes in the competitive and highly
regulated industries in which FOXO operates, variations in
operating performance across competitors or changes in laws and
regulations affecting FOXO’s business; (ii) the ability to
implement FOXO’s business plans, forecasts, and other expectations;
(iii) the ability to obtain financing if needed; (iv) the ability
to maintain its NYSE American listing; (v) the risk that FOXO has a
history of losses and may not achieve or maintain profitability in
the future; (vi) potential inability of FOXO to establish or
maintain relationships required to advance its goals or to achieve
its commercialization and development plans; (vii) the
enforceability of FOXO’s intellectual property, including its
patents and the potential infringement on the intellectual property
rights of others; and (viii) the risk of downturns and a changing
regulatory landscape in the highly competitive biotechnology
industry or in the markets or industries in which FOXO’s
prospective customers operate. The foregoing list of factors is not
exhaustive. Readers should carefully consider the foregoing factors
and the other risks and uncertainties discussed in FOXO’s most
recent reports on Forms 10-K and 10-Q, particularly the “Risk
Factors” sections of those reports, and in other documents FOXO has
filed, or will file, with the SEC. These filings identify and
address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and FOXO assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230719361454/en/
Investor Relations Matthew Hausch, Cody Slach Gateway
Investor Relations (949) 574-3860 FOXO@gatewayir.com
FOXO Technologies (AMEX:FOXO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
FOXO Technologies (AMEX:FOXO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024